Onvatilimab — Investigational Agent
Monoclonal Antibody · Phase 1/2 · NextCure
Mechanism of Action
A humanized monoclonal antibody targeting Siglec-15, an immunosuppressive molecule on tumor cells and myeloid cells, restoring T-cell activation in the tumor microenvironment in a pathway distinct from PD-1/PD-L1.
Investigational Indications
- Advanced or metastatic solid tumors
- Head and neck squamous cell carcinoma
- Endometrial cancer
- Urothelial carcinoma